Monitoring Agency Report for the quarter ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CARE Ratings, the monitoring agency, filed its report for the Rs. 218.70 crore preferential issue of compulsorily convertible warrants allotted in January 2025. The company raised no fresh funds during Q2FY26 and total utilization stood at Rs. 63.17 crore against the Rs. 218.70 crore raised, with Rs. 0.01 crore remaining unutilized. The issue was originally planned at Rs. 1,028.70 crore but was heavily undersubscribed, and the share price is reportedly well below the warrant exercise price, raising the risk of warrants lapsing. The agency flagged several serious concerns including ED raids on promoter Vikas Garg linked to the Mahadev betting app case, an arbitration award of USD 34.83 million against the company in favor of group entity Vikas Lifecare, and an ongoing dispute over USD 40 million of pending FCCB proceeds related to the Ebix Inc. acquisition. The company disputed some of the agency's observations, stating promoters remain the primary warrant subscribers and that disclosures are already in the public domain.
Multiple red flags for shareholders — regulatory scrutiny on the promoter, pending legal liabilities exceeding Rs. 400 crore, risk of warrants lapsing, and frequent management churn could weigh negatively on the stock and shake investor confidence.